GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Jennifer Anne Williams sold 4,911 shares of GenMark Diagnostics stock in a transaction on Monday, February 26th. The shares were sold at an average price of $4.17, for a total transaction of $20,478.87. Following the completion of the transaction, the senior vice president now directly owns 227,122 shares of the company’s stock, valued at approximately $947,098.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Jennifer Anne Williams also recently made the following trade(s):
- On Wednesday, February 21st, Jennifer Anne Williams sold 5,147 shares of GenMark Diagnostics stock. The shares were sold at an average price of $4.40, for a total transaction of $22,646.80.
Shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) traded down $0.16 during trading on Wednesday, reaching $5.32. 163,323 shares of the company’s stock were exchanged, compared to its average volume of 389,287. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.04 and a current ratio of 3.44. The stock has a market cap of $291.51, a P/E ratio of -4.36 and a beta of 0.99. GenMark Diagnostics, Inc has a 52 week low of $3.63 and a 52 week high of $13.67.
GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.26) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.26). GenMark Diagnostics had a negative net margin of 117.77% and a negative return on equity of 91.14%. The business had revenue of $16.02 million during the quarter, compared to the consensus estimate of $15.82 million. equities analysts anticipate that GenMark Diagnostics, Inc will post -0.78 EPS for the current year.
A number of equities research analysts have recently issued reports on the stock. BTIG Research set a $11.00 price target on shares of GenMark Diagnostics and gave the company a “buy” rating in a research note on Monday, November 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of GenMark Diagnostics in a research note on Friday, January 19th. Canaccord Genuity dropped their price objective on shares of GenMark Diagnostics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, February 28th. Zacks Investment Research raised shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday, December 11th. Finally, BidaskClub upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $10.60.
Several institutional investors have recently added to or reduced their stakes in GNMK. TIAA CREF Investment Management LLC boosted its stake in shares of GenMark Diagnostics by 0.8% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 168,888 shares of the medical equipment provider’s stock worth $1,998,000 after purchasing an additional 1,268 shares during the last quarter. Ameriprise Financial Inc. lifted its position in GenMark Diagnostics by 27.1% during the second quarter. Ameriprise Financial Inc. now owns 43,141 shares of the medical equipment provider’s stock valued at $510,000 after buying an additional 9,196 shares in the last quarter. UBS Asset Management Americas Inc. acquired a new position in GenMark Diagnostics during the second quarter valued at approximately $277,000. Northern Trust Corp lifted its position in GenMark Diagnostics by 9.2% during the second quarter. Northern Trust Corp now owns 630,760 shares of the medical equipment provider’s stock valued at $7,462,000 after buying an additional 52,984 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in GenMark Diagnostics by 10.9% during the second quarter. Vanguard Group Inc. now owns 2,169,476 shares of the medical equipment provider’s stock valued at $25,664,000 after buying an additional 212,795 shares in the last quarter.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.